2023
MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas.
Kinslow C, Rae A, Taparra K, Kumar P, Siegelin M, Grinband J, Gill B, McKhann G, Sisti M, Bruce J, Canoll P, Iwamoto F, Horowitz D, Kachnic L, Neugut A, Yu J, Cheng S, Wang T. MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas. Clinical Cancer Research 2023, 29: 4399-4407. PMID: 37611077, PMCID: PMC10872921, DOI: 10.1158/1078-0432.ccr-23-1295.Peer-Reviewed Original ResearchConceptsAssociated with worse survivalOverall survivalMGMT promoter statusUnmethylated MGMTWorse survivalPrognostic of progression-free survivalPromoter statusMultivariate Cox proportional hazards regression modelsWorld Health Organization gradeProgression-free survivalNational Cancer DatabaseCox proportional hazards regression modelsMGMT promoter methylationProportional hazards regression modelsGuiding treatment decisionsHazards regression modelsCourse of treatmentPredictive of responseMultiagent chemotherapyMGMT promoterCancer DatabaseMMGMTAlkylating chemotherapyChemotherapyEligible patients
2019
P78 Treatment-Related Complications of Chemotherapy and Radiotherapy: An Analysis of the Nationwide Emergency Department Sample
Jairam V, Lee V, Park H, Thomas C, Melnick E, Gross C, Presley C, Adelson K, Yu J. P78 Treatment-Related Complications of Chemotherapy and Radiotherapy: An Analysis of the Nationwide Emergency Department Sample. International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e51-e52. DOI: 10.1016/s0360-3016(19)30528-0.Peer-Reviewed Original Research
2018
Treatment-Related Complications of Chemotherapy and Radiation Therapy: An Analysis of the Nationwide Emergency Department Sample
Jairam V, Park H, Yu J. Treatment-Related Complications of Chemotherapy and Radiation Therapy: An Analysis of the Nationwide Emergency Department Sample. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e416-e417. DOI: 10.1016/j.ijrobp.2018.07.1221.Peer-Reviewed Original Research
2015
Pediatric Brainstem Glioma Survival After Definitive Radiation Therapy With or Without Concurrent Chemotherapy: A Nationwide Comparison
Park H, Yeboa D, Lester-Coll N, Corso C, Mancini B, Bindra R, Roberts K, Yu J, Rutter C. Pediatric Brainstem Glioma Survival After Definitive Radiation Therapy With or Without Concurrent Chemotherapy: A Nationwide Comparison. International Journal Of Radiation Oncology • Biology • Physics 2015, 93: e504-e505. DOI: 10.1016/j.ijrobp.2015.07.1836.Peer-Reviewed Original ResearchChange in radiotherapy treatment volumes with initial alkylating chemotherapy in anaplastic gliomas
Jairam V, Rutter C, Yu J, Bindra R. Change in radiotherapy treatment volumes with initial alkylating chemotherapy in anaplastic gliomas. Journal Of Radiation Oncology 2015, 4: 163-167. DOI: 10.1007/s13566-015-0193-8.Peer-Reviewed Original ResearchAdjuvant chemotherapyAnaplastic astrocytomaRT volumeAnaplastic gliomasGlioma patientsMaximal responseAnaplastic glioma patientsRadiotherapy treatment volumesStable diseaseSalvage radiotherapyPathologic factorsHospital recordsChemotherapyPatientsIndependent sample t-testRadiotherapyTarget volumePercentage changeVolumetric reductionTreatment volumeSample t-testProgressionT-testGliomasSalvage
2012
Status Quo—Standard-of-Care Medical and Radiation Therapy for Glioblastoma
Becker K, Yu J. Status Quo—Standard-of-Care Medical and Radiation Therapy for Glioblastoma. The Cancer Journal 2012, 18: 12-19. PMID: 22290252, DOI: 10.1097/ppo.0b013e318244d7eb.Peer-Reviewed Original ResearchConceptsRadiation therapyStandard treatmentMonths of diagnosisCases of glioblastomaDevelopment of temozolomideAdjuvant radiationAdjuvant temozolomideAggressive tumorsImproved survivalTreatment courseChemotherapy agentsSurgical interventionChemotherapeutic agentsCancer morbidityTemozolomideGlioblastomaMonthsSurvivalTherapyTreatmentChemoradiationCytoreductionStuppChemotherapyBiopsy